SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
- PMID: 32562762
- PMCID: PMC7836403
- DOI: 10.1016/j.diabet.2020.06.003
SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
Keywords: Adipose tissue; COVID-19; Inflammation; Ketoacidosis; SGLT2 inhibitor.
Comment on
-
Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports.Diabetes Metab. 2020 Sep;46(4):265-271. doi: 10.1016/j.diabet.2020.05.008. Epub 2020 May 21. Diabetes Metab. 2020. PMID: 32447101 Free PMC article. Review.
References
-
- Bonnet F., Scheen A.J. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab. 2018;44:457–464. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
